Ulcerative colitis — maintenance & biologic therapy
UC maintenance · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
After induction of remission, UC requires ongoing therapy to maintain steroid-free remission and prevent colectomy. Choice escalates from 5-ASA to immunomodulators and advanced (biologic/small-molecule) agents by disease extent and severity.
Red flags
- Increasing frequency/bleeding despite therapy (flare)
- Fever and systemic upset (infection/CMV)
- Features of acute severe colitis (needs admission)
- Dysplasia or mass on surveillance
Assessment
Differential diagnosis
- Crohn's colitis
- Infective colitis (reactivation)
- C. difficile superinfection
- CMV colitis in refractory disease
- Irritable bowel overlap
- Bile acid diarrhoea post-colectomy
Investigations
- Faecal calprotectin for non-invasive monitoring
- FBC, CRP, albumin, U&E, LFTs
- Colonoscopy for mucosal healing and dysplasia surveillance
- Thiopurine metabolites (TPMT/NUDT15) before azathioprine
- Therapeutic drug monitoring of biologics
- Hepatitis B/C, TB and VZV screen before immunosuppression
Management
- Confirm UC extent (proctitis, left-sided, extensive) — this drives choice and route
- Maintain mild-moderate disease with oral ± topical 5-ASA; optimise dose and adherence
- Use topical mesalazine for proctitis/distal disease
- Escalate steroid-dependent/refractory disease to a thiopurine or advanced therapy
- Start a biologic or small molecule (anti-TNF, vedolizumab, ustekinumab, JAK inhibitor, S1P modulator) per severity/comorbidity
- Complete pre-biologic infection screening (hepatitis B/C, TB, VZV) and vaccinate
- Avoid NSAIDs and treat intercurrent infection promptly
- Target steroid-free clinical plus biochemical remission (treat-to-target with calprotectin)
- Monitor for drug toxicity and check therapeutic levels in secondary loss of response
- Enrol in colonoscopic dysplasia surveillance from 8–10 years of extensive colitis
- Give bone protection and vaccination; coordinate with colorectal surgery for refractory disease
Drugs & doses
Mesalazine 2.4–4.8 g PO daily (maintenance ≥2 g/day)
Mesalazine 1 g PR suppository/enema (distal disease)
Azathioprine 2–2.5 mg/kg PO once daily
Infliximab 5 mg/kg IV at 0, 2, 6 weeks then 8-weekly
Vedolizumab 300 mg IV induction then 8-weekly
Tofacitinib 10 mg PO twice daily induction then 5 mg twice daily
Disposition
Specialist IBD clinic with nurse-led monitoring; surgical MDT for refractory/dysplastic disease.
Complications & pitfalls
- Acute severe colitis / toxic megacolon
- Colorectal dysplasia and cancer
- Drug toxicity (myelosuppression, hepatotoxicity, infection)
- Steroid dependence and osteoporosis
- Thromboembolism during active disease
Exam pearls
- Maintenance 5-ASA at an adequate dose reduces both relapse and colorectal cancer risk
- Add topical therapy to oral 5-ASA for better distal mucosal healing
- Check TPMT/NUDT15 before thiopurines to avoid severe myelosuppression
- Treat to a target of mucosal/biochemical healing, not just symptom control
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.